Table 3 Characteristics of new users of dipeptidyl peptidase-4 inhibitors
All Data Sources | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | Total | |
|---|---|---|---|---|---|---|---|---|---|
N | 627 | 1 732 | 3 838 | 10 546 | 9 800 | 9 231 | 6 133 | 41 907 | |
Women, % | 46.1 | 45.6 | 46.8 | 46.6 | 45.4 | 47.0 | 44.1 | 46.0 | |
Mean age | 59.2 | 61.5 | 62.0 | 62.6 | 64.5 | 65.9 | 67.4 | 64.3 | |
Age bands, % | 18-44 | 8.3 | 5.6 | 6.3 | 5.7 | 4.5 | 5.1 | 3.3 | 5.0 |
45-64 | 60.8 | 53.8 | 51.2 | 50.2 | 43.6 | 36.8 | 34.2 | 43.8 | |
65-84 | 30.6 | 39.8 | 41.7 | 42.8 | 49.6 | 53.8 | 57.5 | 48.5 | |
85+ | 0.3 | 0.8 | 0.9 | 1.3 | 2.4 | 4.2 | 5.1 | 2.7 | |
Prior antidiabetic treatmentsa, % | No antidiabetics | 4.6 | 4.8 | 10.3 | 15.7 | 9.9 | 16.0 | 9.6 | 12.4 |
Insulin with/without non-insulin antidiabetics | 4.9 | 6.9 | 11.5 | 16.7 | 22.0 | 22.2 | 16.1 | 18.0 | |
Non-insulin antidiabetic monotherapy | 34.9 | 30.9 | 26.1 | 27.4 | 29.9 | 28.6 | 36.1 | 29.7 | |
≥1 non-insulin antidiabetic | 55.5 | 57.3 | 52.2 | 40.2 | 38.2 | 33.1 | 38.2 | 39.9 | |
Patients with 1 year follow-up (%) | 99.5 | 99.7 | 99.4 | 99.6 | 99.3 | 98.2 | 0.0 | 84.6 | |
Patients with 1 year follow-up, N | 624 | 1 727 | 3 815 | 10 504 | 9 731 | 9 067 | - | 35 468 | |
Following antidiabetic treatmentsb, % | ≥1 additional dispensing of a DPP4i | 87.3 | 89.8 | 84.8 | 86.6 | 88.4 | 80.6 | - | 85.5 |
Persistent use of incretins (any) | 57.2 | 65.5 | 59.1 | 66.7 | 65.3 | 55.4 | - | 62.4 | |
Switcher to a GLP1a | 2.9 | 2.5 | 3.5 | 2.3 | 1.6 | 0.8 | - | 1.9 | |
≥1 additional dispensing of non-incretin antidiabetic | 92.5 | 81.5 | 74.8 | 76.7 | 76.0 | 72.6 | - | 75.8 | |
≥1 additional dispensing of any antidiabetic | 97.0 | 97.3 | 93.0 | 93.4 | 95.3 | 89.9 | - | 93.2 | |